

March 11, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Subject: Outcome of Board Meeting, Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

We wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e. March 11, 2026 has considered and approved the change in designation of Mr. Venkata Rao Sadhanala, DIN: 02906370, from “Whole time Director” to “Managing Director” of the Company for a period of 5 years with effect from March 11, 2026 to 10th March 2031 as per the recommendation of Nomination and Remuneration Committee. Further, the said appointment as Managing Director is subject to the Approval of the Shareholders of the Company in the next General Meeting.

Further, the details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are enclosed herewith in Annexure-I.

The Board Meeting commenced at 4.30 P.M and concluded at 5.30 P.M

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Priyanka Agarwal
Company Secretary & Compliance Officer

Annexure-I

Details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sl.NO	Particulars	Details
1	Reason for Change viz., Appointment, Resignation, Removal, Death or otherwise	Change in Designation from Whole Time Director to Managing Director of the Company.
2	Date of Appointment / Cessation (as applicable) & Terms of Appointment	Appointed w.e.f. March 11, 2026 for a period of 5 years subject to approval of shareholders. Remuneration: he will be paid remuneration of Rs. 30 lakhs p.a including perquisites.
3	Brief Profile (in case of appointment)	Mr. Venkata Rao Sadhanala is a Qualified Chartered Accountant and Company Secretary, having experience with more than 3 decades in the Banking and Finance & FMCG and Pharma Industry. He has vast experience in the field of Project finance, corporate strategies, Mergers & Acquisitions. He has held senior positions in Vanta Bioscience Ltd, Synergy Castings Ltd.
4	Disclosure of relationship between the Directors (in case of appointment as a director)	Not Applicable
5	Disclosure in terms of Regulation 30 read with Clause 7B of Part-A of the Schedule-III of the Regulations	Not Applicable